Scholarlink

Introduction <p>Metabolic associated fatty liver disease (MAFLD) is the most common liver disease in the globe. To date, there are no approved medications for MAFLD, and lifestyle modifications remain the primary strategy for its management. The use of medicinal herbs as dietary supplements for managing MAFLD is currently attracting interest. The aim of this review was to highlight the potential of thyme, oregano, and rosemary (TOR), along with their bioactive compounds, in mitigating MAFLD. The chemical composition of these herbs, their mechanisms of action, and their effects in both preclinical and clinical studies are highlighted.</p> Material and methods <p>To gather relevant literature data, international research databases, such as ScienceDirect, Google Scholar, PubMed, Scopus, and Web of Science, were searched using the following keywords: MAFLD, NAFLD, <i>Thymus</i>, <i>Origanum</i>, <i>Rosmarinus</i>, phytochemicals, and hepatic steatosis.</p> Results <p>The reviewed data indicate that TOR plants are rich in bioactive phytochemicals, including polyphenols and volatile compounds. Thyme and oregano are rich in rosmarinic acid, thymol, and carvacrol. Rosemary, on the other hand, is characterized by its high content of carnosol, carnosic acid, rosmarinic acid, and 1,8-cineole. In vitro and animal studies suggest that the extracts of TOR and their main compounds can ameliorate hepatic steatosis, reduce oxidative stress, suppress apoptosis, and regulate lipid and glucose metabolism. These effects are mediated through the regulation of several signaling pathways and mediators. However, clinical evidence remains limited, with few trials available, and the results are not yet conclusive.</p> Conclusion <p>In conclusion, TOR exhibit substantial potential as adjunctive therapies for MAFLD. While preclinical data are promising, further clinical trials are imperative to validate the efficacy of these herbs on MAFLD and their safety in humans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thyme, oregano, and rosemary: herbs and food supplements for the management of metabolic associated fatty liver disease

  • 期刊论文

  • 发表日期：

    2025年1月6日

查看全文
  • Hamza Elbouny,
  • Ayoub Amssayef,
  • Rania Benjamaa,
  • Mohammed Ajebli,
  • Brahim Ouahzizi,
  • Mohamed Bammou,
  • Khalid Sellam,
  • Chakib Alem

摘要

Introduction

Metabolic associated fatty liver disease (MAFLD) is the most common liver disease in the globe. To date, there are no approved medications for MAFLD, and lifestyle modifications remain the primary strategy for its management. The use of medicinal herbs as dietary supplements for managing MAFLD is currently attracting interest. The aim of this review was to highlight the potential of thyme, oregano, and rosemary (TOR), along with their bioactive compounds, in mitigating MAFLD. The chemical composition of these herbs, their mechanisms of action, and their effects in both preclinical and clinical studies are highlighted.

Material and methods

To gather relevant literature data, international research databases, such as ScienceDirect, Google Scholar, PubMed, Scopus, and Web of Science, were searched using the following keywords: MAFLD, NAFLD, Thymus, Origanum, Rosmarinus, phytochemicals, and hepatic steatosis.

Results

The reviewed data indicate that TOR plants are rich in bioactive phytochemicals, including polyphenols and volatile compounds. Thyme and oregano are rich in rosmarinic acid, thymol, and carvacrol. Rosemary, on the other hand, is characterized by its high content of carnosol, carnosic acid, rosmarinic acid, and 1,8-cineole. In vitro and animal studies suggest that the extracts of TOR and their main compounds can ameliorate hepatic steatosis, reduce oxidative stress, suppress apoptosis, and regulate lipid and glucose metabolism. These effects are mediated through the regulation of several signaling pathways and mediators. However, clinical evidence remains limited, with few trials available, and the results are not yet conclusive.

Conclusion

In conclusion, TOR exhibit substantial potential as adjunctive therapies for MAFLD. While preclinical data are promising, further clinical trials are imperative to validate the efficacy of these herbs on MAFLD and their safety in humans.